Volta Medical, a Marseille, France-based health technology company that leverages artificial intelligence to revolutionize interventional cardiac electrophysiology, announced that it raised €36 million in Series B funding, bringing its total raised to more than €70 million.
The round was led by U.S.-based Vensana Capital, with participation from Lightstone Ventures and existing investor Gilde Healthcare.
The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialization, and pursue further regulatory approvals
The new funding will support technology platform expansion and further validate VX1 Volta’s artificial intelligence (AI) decision-support software in improving catheter ablation for complex cardiac arrhythmias.
The company’s lead product, VOLTA VX1, is the first commercially available AI decision-support software to help guide physicians with the identification and real-time annotation of unique abnormalities (so-called “dispersed electrograms”) on 3D anatomical and electrical maps of the heart.
“There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF,” said Theophile Mohr Durdez, CEO and co-founder of Volta Medical. “With half of these patients requiring repeat treatments, clinicians need tools that enable them to better understand the disease and drastically improve patient outcomes. We believe VOLTA’s VX1 has the potential to do just that in a consistent, reproducible way. We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.”
Volta Medical is also pleased to announce the appointment of experienced medical device executive John Slump as CFO of Volta Medical.
Company: Volta Medical SAS
Raised: €36.0M
Round: Series B
Funding Month: January 2023
Lead Investors: Vensana Capital
Additional Investors: Lightstone Ventures and Gilde Healthcare
Company Website: https://www.volta-medical.com/
Software Category: AI Software for Cardiac Ablation
About the Company: Founded in 2016 by three physicians and a data scientist, Volta Medical is a health technology company developing AI software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Its cutting-edge software solutions use a machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. The company’s first product, VX1, is a digital AI companion device and algorithm to assist cardiologists with the real-time identification of specific abnormal electrograms (EGMs), known as dispersed EGMs. Volta Medical is headquartered in Marseille, France.
Source: http://www.volta-medical.com/ Press Release